Small molecule · Inhibitor of protein arginine methyltransferase 5 (PRMT5) · developed by Prelude Therapeutics
PRT543 is an orally available small molecule that selectively binds the substrate recognition site of PRMT5 and inhibits its methyltransferase activity, reducing methylated arginine on histones H2A, H3 and H4. It is being studied in relapsed or refractory solid tumors, lymphomas, myeloid malignancies and adenoid cystic carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03886831 | Phase 1 | Relapsed/Refractory Advanced Solid Tumors | Completed | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adenoid Cystic CarcinomaRefractory Chronic Myelomonocytic LeukemiaRelapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Advanced Solid TumorsRelapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory MyelodysplasiaRelapsed/Refractory Myelofibrosis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →